Semafore Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Semafore Pharmaceuticals Inc. - overview
Established
2000
Location
Indianapolis, IN, US
Primary Industry
Pharmaceuticals
About
Semafore Pharmaceuticals Inc. is focused on developing innovative pharmaceutical solutions to address unmet medical needs, particularly in chronic disease treatment. The company actively engages healthcare providers to enhance patient care and access. Founded in 2000 and based in Indianapolis, US, Semafore Pharmaceuticals Inc.
specializes in pharmaceutical development. The company has participated in 2 deals, with its most recent being a Series B funding round in April 2007, raising USD 2. 50 mn, which valued the company at USD 22. 485 mn post-money.
Semafore Pharmaceuticals specializes in the development and commercialization of pharmaceutical products aimed at addressing unmet medical needs across various therapeutic areas. Its core offerings include prescription medications designed to treat chronic conditions, particularly targeting diseases that lack effective treatments. These products are distributed to healthcare providers, including hospitals and clinics, throughout North America and Europe, ensuring compliance with market standards. Semafore Pharmaceuticals generates revenue through direct sales to healthcare providers and partnerships with larger pharmaceutical distributors.
The company operates on a B2B basis, supplying hospitals and clinics that dispense its products to patients. By implementing competitive pricing strategies for its flagship products, Semafore Pharma ensures its offerings are well-positioned in the market, with streamlined distribution facilitated through contracts, yielding predictable revenue flows. Looking ahead, Semafore Pharmaceuticals plans to leverage the recent Series B funding of USD 2. 50 mn, secured in April 2007, to develop and launch new products aimed at addressing chronic conditions.
The company is also targeting expansion into additional markets in Europe and North America by 2025. This strategy aims to enhance the availability of its pharmaceutical offerings, ensuring that they meet the needs of both healthcare professionals and patients.
Current Investors
Twilight Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.semaforepharma.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.